RGNX•benzinga•
Regenxbio Announced New Interim Data From The Phase 1/2 Affinity Duchenne Trial. Updates Include Positive Functional, Safety And Biomarker Data For RGX-202, The Functional Data Demonstrate Consistent Benefit Among Dose Level 2 Participants At 9 And 12 Mon
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga